{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:57:48Z","timestamp":1772063868866,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,25]]},"DOI":"10.7759\/cureus.104253","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:15:37Z","timestamp":1772061337000},"source":"Crossref","is-referenced-by-count":0,"title":["Extranodal Natural Killer (NK)\/T-Cell Lymphoma Causing Severe Facial Destruction Refractory to Chemotherapy and Immunotherapy"],"prefix":"10.7759","author":[{"given":"Ryan A","family":"Tiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan F","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435024","article-title":"Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK\/T-cell lymphoma patients receiving primary radiotherapy","volume":"120","author":"Wang ZY","year":"2012","unstructured":"Wang ZY, Liu QF, Wang H, et al.. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK\/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012, 120:2003-10. 10.1182\/blood-2012-06-435024","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.11.007","article-title":"Clinical features and current optimal management of natural killer\/T-cell lymphoma","volume":"31","author":"Makita S","year":"2017","unstructured":"Makita S, Tobinai K. Clinical features and current optimal management of natural killer\/T-cell lymphoma. Hematol Oncol Clin. 2017, 31:239-53. 10.1016\/j.hoc.2016.11.007","journal-title":"Hematol Oncol Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00011-0","article-title":"Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study","volume":"12","author":"Malpica L","year":"2025","unstructured":"Malpica L, Idrobo H, Pavlovsky A, et al.. Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study. Lancet Haematol. 2025, 12:258-68. 10.1016\/S2352-3026(25)00011-0","journal-title":"Lancet Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103237","article-title":"Extranodal NK\/T cell lymphoma, nasal type: an updated overview","volume":"159","author":"S\u00e1nchez-Romero C","year":"2021","unstructured":"S\u00e1nchez-Romero C, Bologna-Molina R, Paes de Almeida O, et al.. Extranodal NK\/T cell lymphoma, nasal type: an updated overview. Crit Rev Oncol Hematol. 2021, 159:103237. 10.1016\/j.critrevonc.2021.103237","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp418","article-title":"Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type","volume":"21","author":"Suzuki R","year":"2010","unstructured":"Suzuki R, Suzumiya J, Yamaguchi M, et al.. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010, 21:1032-40. 10.1093\/annonc\/mdp418","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(02)02916-4","article-title":"Early stage nasal NK\/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality","volume":"54","author":"Cheung MM","year":"2002","unstructured":"Cheung MM, Chan JK, Lau WH, et al.. Early stage nasal NK\/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002, 54:182-90. 10.1016\/s0360-3016(02)02916-4","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan","volume":"35","author":"Yamaguchi M","year":"2017","unstructured":"Yamaguchi M, Suzuki R, Oguchi M, et al.. Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017, 35:32-9. 10.1200\/JCO.2016.68.1619","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1388564","article-title":"Analysis of the treatment and prognosis of 266 cases of extranodal natural killer\/T-cell lymphoma, nasal type in a single medical center","volume":"14","author":"Yang L","year":"2024","unstructured":"Yang L, Wei L, Li X, et al.. Analysis of the treatment and prognosis of 266 cases of extranodal natural killer\/T-cell lymphoma, nasal type in a single medical center. Front Oncol. 2024, 14:1388564. 10.3389\/fonc.2024.1388564","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8647","article-title":"Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-GEMOX regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma","volume":"7","author":"Wang JH","year":"2016","unstructured":"Wang JH, Wang L, Liu CC, et al.. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-GEMOX regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma. Oncotarget. 2016, 7:29092-101. 10.18632\/oncotarget.8647","journal-title":"Oncotarget"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.06.005","article-title":"NK\/T-cell lymphomas","volume":"32","author":"Tse E","year":"2019","unstructured":"Tse E, Kwong YL. NK\/T-cell lymphomas. Best Pract Res Clin Haematol. 2019, 32:253-61. 10.1016\/j.beha.2019.06.005","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong YL","year":"2017","unstructured":"Kwong YL, Chan TS, Tan D, et al.. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017, 129:2437-42. 10.1182\/blood-2016-12-756841","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184325","article-title":"Pembrolizumab in relapsed\/refractory extranodal NK\/T cell lymphoma and mature T cell lymphoma: a prospective phase II study","volume":"142","author":"Chan T","year":"2023","unstructured":"Chan T, Tse E. Pembrolizumab in relapsed\/refractory extranodal NK\/T cell lymphoma and mature T cell lymphoma: a prospective phase II study. Blood. 2023, 142:1726. 10.1182\/blood-2023-184325","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2000.00307.x","article-title":"Angiocentric nasal T\/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients","volume":"22","author":"Avil\u00e9s A","year":"2000","unstructured":"Avil\u00e9s A, D\u00edaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T\/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000, 22:215-20. 10.1046\/j.1365-2257.2000.00307.x","journal-title":"Clin Lab Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh143","article-title":"Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: a single institute survey in Taiwan","volume":"15","author":"You JY","year":"2004","unstructured":"You JY, Chi KH, Yang MH, et al.. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)\/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004, 15:618-25. 10.1093\/annonc\/mdh143","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee J","year":"2006","unstructured":"Lee J, Suh C, Park YH, et al.. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006, 24:612-8. 10.1200\/JCO.2005.04.1384","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1401","article-title":"Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index","volume":"103","author":"Chim CS","year":"2004","unstructured":"Chim CS, Ma SY, Au WY, et al.. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004, 103:216-21. 10.1182\/blood-2003-05-1401","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7575","article-title":"Clinical characteristics, survival outcomes, and prognostic factors in extranodal natural killer\/T-cell lymphoma, nasal type: the National Cancer Database study (2004-2019)","volume":"41","author":"Baidoun F","year":"2023","unstructured":"Baidoun F, Hoppe B, Peterson J, et al.. Clinical characteristics, survival outcomes, and prognostic factors in extranodal natural killer\/T-cell lymphoma, nasal type: the National Cancer Database study (2004-2019). J Clin Oncol. 2023, 41:7575. 10.1200\/JCO.2023.41.16_suppl.7575","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4197","article-title":"Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients","volume":"104","author":"Au WY","year":"2004","unstructured":"Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004, 104:243-9. 10.1182\/blood-2003-12-4197","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1563690","article-title":"Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK\/T-cell lymphoma treated with P-GEMOX protocol","volume":"60","author":"Wang XX","year":"2019","unstructured":"Wang XX, Li PF, Bai B, et al.. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK\/T-cell lymphoma treated with P-GEMOX protocol. Leuk Lymphoma. 2019, 60:1917-25. 10.1080\/10428194.2018.1563690","journal-title":"Leuk Lymphoma"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim SJ","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A, et al.. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016, 17:389-400. 10.1016\/S1470-2045(15)00533-1","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/456922-extranodal-natural-killer-nkt-cell-lymphoma-causing-severe-facial-destruction-refractory-to-chemotherapy-and-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:15:39Z","timestamp":1772061339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/456922-extranodal-natural-killer-nkt-cell-lymphoma-causing-severe-facial-destruction-refractory-to-chemotherapy-and-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.104253","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}